(Circulation. 1995;91:2898-2903.)
© 1995 American Heart Association, Inc.
Articles |
From the Department of Medicine, University of Manchester, England.
Correspondence to Prof A.M. Heagerty, MD, FRCP, Department of Medicine, Withington Hospital, Nell Lane, West Didsbury, Manchester, UK, M20 8LR.
| Abstract |
|---|
|
|
|---|
Methods and Results Subcutaneous gluteal fat biopsies were taken from 18 hypercholesterolemic (HC) patients (mean±SEM serum total cholesterol, 9.7±0.57 mmol/L) and 16 age- and sex-matched control subjects (mean cholesterol, 4.69±0.18 mmol/L). Subcutaneous small arteries (internal diameter, <330 µm) were dissected and mounted on a wire myograph for isometric tension measurements. The HC patients showed impaired relaxation to acetylcholine (10-9 to 10-6 mol/L) after preconstriction with the thromboxane A2 analogue U46619 (10-6 mol/L, mean maximum relaxation, 42.9±5.4%) compared with control subjects (85.7±4.0%, P<.00001). Incubation with the nitric oxide substrate L-arginine (3 mmol/L) improved the endothelium-dependent vasorelaxation response to acetylcholine (70.9±6.0%, P<.01) in patients but not in control subjects. Also, there was a smaller but significant difference in responses to the endothelium-independent agent sodium nitroprusside (10-9 to 10-6 mol/L) between the HC group (mean maximum relaxation, 76.9±6.0%) and the control subjects (89.7±6%; P<.01). A total of 10 patients had a second gluteal skin biopsy and repeat functional studies after successful cholesterol-lowering therapy after a mean period of 9.9±4.7 months. A significant reduction in total and LDL cholesterol was achieved (5.29±0.2 and 3.23±0.21 mmol/L, respectively; P<.001). This restored vasorelaxation to control values in response to both acetylcholine (mean maximum relaxation, 83.3±3.8%; P<.0001) and sodium nitroprusside (87.9±4.8%, P<.01). Although both groups were normotensive, there were significantly higher blood pressures in the HC group compared with control subjects (139±4.1 versus 123±3.0 mm Hg systolic, P<.01; 84±1.3 versus 75±2.2 mm Hg diastolic, P<.01). There was no difference in initial blood pressures between the entire group of 18 and the 10 patients who had repeat biopsies. The blood pressures fell to control values after cholesterol reduction (129.33±4.93 mm Hg systolic and 72.33±2.93 diastolic mm Hg, P<.02 relative to pretreatment values).
Conclusions These results demonstrate abnormalities of both endothelium-dependent and -independent relaxation in human peripheral small arteries that are normalized with effective lipid lowering. The changes in blood pressure may have been secondary to the improvement in vascular function.
Key Words: hypercholesterolemia endothelium blood pressure arteries
| Introduction |
|---|
|
|
|---|
It is of further interest that studies of hyperlipidemia in animals suggest that the endothelial dysfunction can be reversed with treatment,7 8 and two studies in humans have reported that reduction of serum cholesterol can improve epicardial coronary artery dilatation9 and coronary blood flow.10 However, there have been no in vitro studies of small arteries from patients with hyperlipidemia either before or after treatment.
This in vitro study adds important data to the in vivo forearm blood flow studies. The technique allows isolated intact small arteries, which are believed to be important as peripheral resistance vessels, to be studied free from confounding influences such as heart rate, varying blood flow, forearm length, and uncertain drug delivery. These isolated vessel techniques offer significant advantages for pharmacological studies.
The purposes of the present study were (1) to examine in vitro the contractile and relaxing properties of small resistance arteries from patients with hypercholesterolemia before and during therapy and (2) to elucidate whether both endothelium-dependent and -independent dilator functions were impaired in hypercholesterolemia, because this is controversial in humans.11 The results indicate that both processes are affected and that treatment can restore their integrity relatively quickly. Moreover, there are interesting effects on systemic arterial blood pressure that may lead to new avenues of research.
| Methods |
|---|
|
|
|---|
This study population was compared with 16 healthy age- and sex-matched control subjects who were selected on the basis of having a total serum cholesterol of <5.2 mmol/L. These individuals responded to an advertisement placed in a local newspaper.
Patients and control subjects underwent complete clinical examination and had blood drawn for a fasting lipid profile and lipid subfraction analysis. Blood pressure was recorded from the right arm with the use of a standard mercury sphygmomanometer with the participant in the seated position after a 15-minute rest. All patients were seen between 8:30 and 11:00 AM, and the mean value of three successive readings was noted.
Small Artery Study
A sample of skin and underlying gluteal
fat was taken with the
participant under local anesthetic as previously
described.12 The specimen was immediately placed into a
cold physiological salt solution (PSS) of the following composition (in
mmol/L): 119 NaCl, 25 NaH2CO3, 4.7 KCl,
1.18 KH2PO4, 1.17
MgSO4, 2.5 CaCl2, 5.5 glucose,
and 0.026 EDTA.
Intact small arterial segments 2 mm long were then dissected while under a light microscope and mounted as ring preparations in a wire myograph.12 Vessels were kept at 37°C in PSS gassed with 95% O25% CO2 to maintain a constant pH 7.45.
The vessel was set to an internal circumference
(Lo)
as determined previously to allow isometric tension
experiments.13 The circumference that the vessels would
have had in vivo when relaxed and under a transmural pressure of 100
mm Hg (L100) was found with the use of the law of Laplace
(
P=
T/r where
P is
transmural
pressure,
T is tension, and r is radius). Lo was then
taken as 0.9 L100 and the normalized internal diameter was
taken as Lo/
.
The vessels were stimulated three times (2 minutes) with 5 µmol/L norepinephrine for assessment of tissue viability.
Pharmacological Protocol
Constrictor function was examined by
cumulative dose-response
determinations to norepinephrine and the thromboxane analogue U46619
(10-9 to 10-5 mol/L). Vasodilation was
assessed by constructing dose-response curves to acetylcholine
(endothelium-dependent) and sodium nitroprusside
(endothelium-independent) in increasing concentrations
((10-9 to 10-5 mol/L) after a stable
preconstriction with U46619 10-6 mol/L. Vessels were then
incubated with the nitric oxide substrate L-arginine (3
mmol/L) for 30 minutes, and the dose-response curve to acetylcholine
was repeated.
The hypercholesterolemic patients then began receiving appropriate drug treatment and were followed up on a routine basis at 3-month intervals by physicians in the lipid clinic. When a satisfactory lipid profile had been achieved, a second skin biopsy was taken and the functional studies were repeated. We had no control of the hypolipidemic medication chosen and were interested in cholesterol reduction, not specific drug effects.
All patients and control subjects were fully informed of the nature of the study and gave written consent. The study was approved by the local ethics committee.
Statistical Analysis
Values are given as mean±SEM.
ANOVA for repeated measures was
used to compare dose-response curves. Student's t tests
were used to compare paired or unpaired data. Linear regression
analysis was performed for selected variables. A value of
P<.05 was considered to indicate significance.
| Results |
|---|
|
|
|---|
|
Pretreatment Small Artery Study
Contractile Function
Small artery internal diameters were similar for the two groups
(312±10 versus 316±12 µm). There were no significant
differences in
contractile vascular responses between the two groups to either
norepinephrine or U46619 (Figs 1
and 2
).
|
|
Dilator Function
The arteries from
hypercholesterolemic patients had markedly
impaired endothelium-dependent relaxation compared with
responses for vessels from control subjects. The mean maximum
relaxation to acetylcholine was 85.7±4.0% in the control group and
49.9±5.4% in the group of hypercholesterolemic patients (Fig
3
). In all participants in the small artery study, there
were significant correlations of both total serum cholesterol and LDL
cholesterol with the degree of endothelial dysfunction (maximum
relaxation to acetylcholine) (r=.753, P<.0001;
r=.785, P<.0001, respectively). There was no
correlation between HDL or LDL-to-HDL ratio and endothelial function.
There also was no correlation between nonendothelial function and any
lipid fraction.
|
In arteries from patients with hypercholesterolemia,
there was a
significant impairment in endothelium-independent
relaxation provoked by sodium nitroprusside (Fig
4
).
|
Response to L-Arginine
Preincubation with L-arginine (3 mmol/L) improved
acetylcholine-induced endothelium-dependent relaxation
in small arteries from hypercholesterolemic subjects (mean maximum
relaxation, 70.9±6.0%; P<.01) but did not restore the
dysfunction to normal values (P<.02) (Fig 5
).
L-Arginine had no effect on the
responses from vessels from control subjects, and in fact the
sensitivity curve was shifted to the right (Fig 5
), although
this did
not attain statistical significance.
|
Posttreatment Small Artery Study
A total of 10 patients
underwent successful treatment according to
European Atherosclerosis Society guidelines with significant reduction
in both total and LDL cholesterol to 5.29±0.2 and 3.23±0.21
mmol/L,
respectively (Table 2![]()
)
(P<.001), and the patients agreed to undergo a second
biopsy to permit the in vitro examination of peripheral small arteries
after normalization of their lipid profiles. Two patients refused to
undergo a repeat procedure, and 1 patient was lost to follow-up. So
far, the remaining patients have failed to respond adequately to
treatment, as judged by the treating physician. The drug treatments
used are shown in Table 2
.
|
|
The average time for
treatment to normalize lipids was 9.9±4.7 months.
Examination of the responses of the preconstricted small arteries to
incremental concentrations of acetylcholine demonstrated that the
previously impaired endothelium-dependent relaxation
was restored to that seen in the control population (Fig 6
).
Similarly, endothelium-independent
relaxation effected by challenging the preconstricted vessels with
sodium nitroprusside was completely returned to normal values (Fig
7
).
|
|
Despite the lack of change in body weight during therapy for the 10 patients reexamined (69.3±2.2 versus 69.5±2.3 kg), it was of interest that mean systolic and diastolic blood pressures both fell significantly (7.7±2.7 and 6.9±2.3 mm Hg, respectively; P<.02). The blood pressures of the control subjects remained the same when taken at a later date (123±5.0 mm Hg systolic and 77±3.6 mm Hg diastolic). There did not appear to be any correlation between the magnitude of cholesterol reduction and the degree of blood pressure drop.
| Discussion |
|---|
|
|
|---|
The mechanism by which an abnormal lipid profile impairs arterial function has been the subject of considerable attention. It is important to bear in mind that, although endothelium-dependent dilatation is most affected, endothelium-independent relaxation is also influenced, albeit to a lesser extent. With regard to endothelium-dependent relaxation, it appears that there must be a reduced bioavailability of nitric oxide. This is synthesized from the substrate L-arginine,14 and it has been demonstrated that an infusion of L-arginine can restore endothelium-dependent relaxation to normal levels in hypercholesterolemic rabbits.15 Furthermore, similar findings have been reported in the human coronary circulation16 and the forearm vasculature.17 However, in the present study, preincubation in vitro with L-arginine improved endothelial integrity slightly but did not restore normal function. In addition, it has been observed that hypercholesterolemia produces an increase in the release of nitrosylated compounds from the rabbit aorta.18 Therefore, it appears that there is evidence that nitric oxide synthesis is enhanced in hypercholesterolemia but that its degradation is faster or it is released in a less bioactive form. Ultimately, the vasodilatation brought about by these endothelial factors occurs via the same mechanism activated by endothelium-independent agonists such as sodium nitroprusside, ie, by stimulation of guanylate cyclase within vascular myocytes and formation of a nitrosyl-porphyrin complex.19 20 The activity of guanylate cyclase may be affected directly by hypercholesterolemia as a result of a change in the redox state of the vascular smooth muscle.21 Therefore, there is an emerging body of evidence to suggest that increased serum cholesterol levels can interfere with vascular dilator mechanisms at a variety of points.22 In further study, we would like to examine vasodilators that do not act through nitric oxide release.
The exact lipid fraction that is responsible for these findings also is uncertain. It seems clear that triglycerides are not contributing, as we have shown little change in triglyceride profiles after treatment yet demonstrated good functional improvement. Among the cholesterol subfractions, the most likely candidate is the oxidized LDL fraction. Recently, it has been reported that oxidized LDL could attenuate endothelium-dependent relaxation in vitro.23 24 This impairment could be overcome by HDL. Zeiher et al25 have also shown that elevated HDL cholesterol levels ameliorate abnormal vasoconstriction in human coronary arteries. High levels of oxidized LDL may generate free radical species from endothelial cells,26 and it is known that superoxide anions in particular are released from vessels from hypercholesterolemic animals and that they can inactivate nitric oxide.27 This theory is supported by the work of Raij et al,28 which has demonstrated that hypercholesterolemia promoted endothelial dysfunction in vitamin Edeficient (a potent antioxidant) and selenium-deficient rats, and this work provides further evidence for an attack on guanylate cyclase activity being central to the mechanism underlying this phenomenon.
Treatment of hypercholesterolemia with drug therapy restored the lipid profile of 10 of the study population to normal levels within months, and this was associated with improved endothelium-dependent and -independent dilator function and a decrease in systemic arterial blood pressure. Given the above evidence, the most likely explanation is that a reduction in available LDL cholesterol lowers its oxidation potential and generates free radical species. In this regard, there is increasing evidence for the protective effects of antioxidants such as vitamin E in heart disease29 30 and in vitro studies.28 31 Certainly, these dramatic improvements in arterial function have been accomplished within a time frame much shorter than that required to observe the regression of atheromatous plaques and suggest that more wide-ranging improvements in circulatory integrity are possible with control of an abnormal lipid profile.
In summary, in vitro studies of small arteries from patients with hypercholesterolemia demonstrate abnormalities of both endothelium-dependent and -independent relaxation but normal vascular sensitivity to vasoconstrictor agents. Therefore, it is possible that the deficit is one of guanylate cyclase activation, although we have provided no conclusive evidence for this here. Normalizing the lipids restores arterial function to normal relatively rapidly, and this may explain the fall in blood pressure recorded. In any event, the improvement in vascular function may be important from the clinical perspective of blood pressure homeostasis, and we suggest that studies be designed to look into possible blood pressurelowering effects of hypolipidemic agents.
| Acknowledgments |
|---|
Received November 1, 1994; accepted December 20, 1994.
| References |
|---|
|
|
|---|
2.
Zeiher AM, Drexler H, Wollschager H, Just H.
Modulation of coronary vasomotor tone in humans: progressive
endothelial dysfunction with different early stages of coronary
atherosclerosis. Circulation. 1991;83:391-401.
3. Creager MA, Cooke JP, Mendlesohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990;86:228-234.
4. Lehmann ED, Watts GF, Fatemi-Langroudi B, Gosling RG. Aortic compliance in young patients with heterozygous familial hypercholesterolemia. Clin Sci. 1992;83:717-721.[Medline] [Order article via Infotrieve]
5. Celermajer DS, Sorensen KE, Gooch UM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Noninvasive defection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-1115. [Medline] [Order article via Infotrieve]
6.
Bonaa KH, Thelle DS. Association between blood
pressure and serum lipids in a population: the Tromso Study.
Circulation. 1991;83:1305-1314.
7. Osborne JA, Lento PH, Siefried MR, Stahl GL, Fusman B, Lefer AM. Cardiovascular effects of acute hypercholesterolemia in rabbits: reversal with lovastatin treatment. J Clin Invest. 1989;83:465-473.
8. Harrison DG, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest. 1987;80:1808-1811.
9. Leung W-H, Lau C-P, Wong C-K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet. 1993;341:1496-1500. [Medline] [Order article via Infotrieve]
10.
Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S,
Inou T, Takeshia A. Reduction in serum cholesterol with
pravastatin improves endothelium-dependent coronary
vasomotion in patients with hypercholesterolemia.
Circulation. 1994;89:2519-2524.
11. Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet. 1992;340:1430-1432. [Medline] [Order article via Infotrieve]
12. Aalkjaer C, Pedersen EB, Danielsen H. Morphological and functional characteristics of isolated resistance vessels in advanced uraemia. Clin Sci. 1986;71:657-663. [Medline] [Order article via Infotrieve]
13.
Mulvany MJ, Halpern W. Contractile properties of
small arterial resistance vessels in spontaneously hypertensive and
normotensive rats. Circ Res. 1977;41:19-26.
14.
Moncada S, Higgs A. The
L-arginine-nitric oxide pathway. N Engl J
Med. 1993;329:2002-2012.
15.
Cook JP, Andon NA, Girerd XJ, Hirsh AT, Creager MA.
Arginine restores cholinergic relaxation of hypercholesterolemic
rabbit thoracic aorta. Circulation. 1991;83:1057-1062.
16. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in the coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. 1991;338:1546-1550. [Medline] [Order article via Infotrieve]
17. Creager MA, Gallagher SJ, Girerd XJ, Colman SM, Dzau VJ, Cooke JP. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90:1248-1253.
18. Minor RL, Myers PR, Gyerra R, Bates JN, Harrison DG. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest. 1990;86:2109-2119.
19. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest. 1986;73:1-5.
20. Waldman S, Murad F. Biochemical mechanisms underlying vascular smooth muscle relaxation: the guanylate cyclase-cyclic GMP system. J Cardiovasc Pharmacol. 1988;12(suppl 15):5115-5118.
21. Witzaum JL, Steinberg D. Evidence for the presence of oxidatively modified LDL in human atherosclerotic lesions. Circulation. 1989;80(suppl II):II-160. Abstract.
22.
Flavahan NA. Atherosclerosis or
lipoprotein-induced endothelial dysfunction potential mechanism
underlying reduction in EDRF/nitric oxide activity.
Circulation. 1992;85:1927-1938.
23. Simon BC, Cunningham LD, Cohen RA. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest. 1990;86:75-79.
24.
Galle J, Öchsle M, Schollmeyer P, Wanner C.
Oxidized lipoproteins inhibit
endothelium-dependent vasodilation effects of pressure
and high density lipoprotein.
Hypertension. 1994;23:556-564.
25.
Zeiher AM, Schächinger V, Hohnloser SH, Saurbier
B, Just H. Coronary atherosclerotic wall thickening and vascular
reactivity in humans. Circulation. 1994;89:2525-2532.
26. Stewart DJ, Monge JC. Hyperlipidaemia and endothelial dysfunction. Curr Opin Lipid. 1993;4:319-324.
27. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546-2551.
28.
Raij L, Nagy J, Coffee K, Demaster EC.
Hypercholesterolemia promotes endothelial dysfunction in vitamin
E and selenium-deficient rats.
Hypertension. 1993;22:56-61.
29.
Stampfer MJ, Hennekens CH, Manson JE, Colditz GA,
Rosner B, Willett WC. Vitamin E consumption and the risk of
coronary disease in women. N Engl J Med. 1993;328:1444-1449.
30.
Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E,
Colditz GA, Willett WC. Vitamin E consumption and the risk of
coronary heart disease in men. N Engl J Med. 1993;328:1450-1456.
31.
Belcher JD, Balla J, Balla G, Jacobs DR Jr, Gross M,
Jacob HS, Vercellotti M. Vitamin E, LDL, and endothelium: brief
oral vitamin supplementation prevents oxidized LDL-mediated vascular
injury in vitro. Arterioscler Thromb. 1993;13:1779-1789.
This article has been cited by other articles:
![]() |
A. N. Paisley, A. S. Izzard, I. Gemmell, K. Cruickshank, P. J. Trainer, and A. M. Heagerty Small Vessel Remodeling and Impaired Endothelial-Dependent Dilatation in Subcutaneous Resistance Arteries from Patients with Acromegaly J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1111 - 1117. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Sen, N. Tyagi, M. Kumar, K. S. Moshal, W. E. Rodriguez, and S. C. Tyagi Cystathionine- -synthase gene transfer and 3-deazaadenosine ameliorate inflammatory response in endothelial cells Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1779 - C1787. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A.J. van der Linde, E. J.G. Sijbrands, F. Boomsma, and A. H. van den Meiracker Effect of Low-Density Lipoprotein Cholesterol on Angiotensin II Sensitivity: A Randomized Trial With Fluvastatin Hypertension, June 1, 2006; 47(6): 1125 - 1130. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Malik, I. J. Schofield, A. Izzard, C. Austin, G. Bermann, and A. M. Heagerty Effects of Angiotensin Type-1 Receptor Antagonism on Small Artery Function in Patients With Type 2 Diabetes Mellitus Hypertension, February 1, 2005; 45(2): 264 - 269. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M.R. Gill, A. Al-Mamari, W. R. Ferrell, S. J. Cleland, C. J. Packard, N. Sattar, J. R. Petrie, and M. J. Caslake Effects of prior moderate exercise on postprandial metabolism and vascular function in lean and centrally obese men J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2375 - 2382. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bahring, A. Rauch, O. Toka, C. Schroeder, C. Hesse, H. Siedler, G. Fesus, W. E. Haefeli, A. Busjahn, A. Aydin, et al. Autosomal-Dominant Hypertension With Type E Brachydactyly Is Caused by Rearrangement on the Short Arm of Chromosome 12 Hypertension, February 1, 2004; 43(2): 471 - 476. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Holemans, L. Aerts, and F. A. Van Assche Fetal Growth Restriction and Consequences for the Offspring in Animal Models Reproductive Sciences, October 1, 2003; 10(7): 392 - 399. [Abstract] [PDF] |
||||
![]() |
K Holemans, L Aerts, and F A Van Assche Lifetime consequences of abnormal fetal pancreatic development J. Physiol., February 15, 2003; 547(1): 11 - 20. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Schofield, R. Malik, A. Izzard, C. Austin, and A. Heagerty Vascular Structural and Functional Changes in Type 2 Diabetes Mellitus: Evidence for the Roles of Abnormal Myogenic Responsiveness and Dyslipidemia Circulation, December 10, 2002; 106(24): 3037 - 3043. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A Van Assche, K. Holemans, and L. Aerts Long-term consequences for offspring of diabetes during pregnancy Br. Med. Bull., November 1, 2001; 60(1): 173 - 182. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Koh Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability Cardiovasc Res, September 1, 2000; 47(4): 648 - 657. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Schiffrin, J. B. Park, H. D. Intengan, and R. M. Touyz Correction of Arterial Structure and Endothelial Dysfunction in Human Essential Hypertension by the Angiotensin Receptor Antagonist Losartan Circulation, April 11, 2000; 101(14): 1653 - 1659. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. Peterson, M. Courtois, L. F. Peterson, M. R. Peterson, V. G. Dávila-Román, R. J. Spina, and B. Barzilai Estrogen Increases Hyperemic Microvascular Blood Flow Velocity in Postmenopausal Women J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2000; 55(3): 174M - 179. [Abstract] [Full Text] |
||||
![]() |
S. E. Brett, J. M. Ritter, and P. J. Chowienczyk Diastolic Blood Pressure Changes During Exercise Positively Correlate With Serum Cholesterol and Insulin Resistance Circulation, February 15, 2000; 101(6): 611 - 615. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Khan, S. J Litchfield, P. A Stonebridge, and J. J. Belch Lipid-lowering and skin vascular responses in patients with hypercholesterolaemia and peripheral arterial obstructive disease Vascular Medicine, November 1, 1999; 4(4): 233 - 238. [Abstract] [PDF] |
||||
![]() |
S. J Duffy, G. New, R. W Harper, and I. T Meredith Metabolic vasodilation in the human forearm is preserved in hypercholesterolemia despite impairment of endothelium-dependent and independent vasodilation Cardiovasc Res, August 15, 1999; 43(3): 721 - 730. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cooper and A. M. Heagerty Endothelial dysfunction in human intramyocardial small arteries in atherosclerosis and hypercholesterolemia Am J Physiol Heart Circ Physiol, October 1, 1998; 275(4): H1482 - H1488. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. M. FARACI and D. D. HEISTAD Regulation of the Cerebral Circulation: Role of Endothelium and Potassium Channels Physiol Rev, January 1, 1998; 78(1): 53 - 97. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. K. Goode, S. Garcia, and A. M. Heagerty Dietary Supplementation With Marine Fish Oil Improves In Vitro Small Artery Endothelial Function in Hypercholesterolemic Patients : A Double-Blind Placebo-Controlled Study Circulation, November 4, 1997; 96(9): 2802 - 2807. [Abstract] [Full Text] |
||||
![]() |
V. Guetta and R. O. Cannon III Cardiovascular Effects of Estrogen and Lipid-Lowering Therapies in Postmenopausal Women Circulation, May 15, 1996; 93(10): 1928 - 1937. [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |